Skip to main content

Drug Interactions between AmBisome and rapacuronium

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

amphotericin B liposomal rapacuronium

Applies to: AmBisome (amphotericin b liposomal) and rapacuronium

MONITOR: Amphotericin commonly causes renal potassium and magnesium wasting. As a result, serum potassium is decreased, and the pharmacologic effects of some neuromuscular blocking agents are enhanced.

MANAGEMENT: To decrease or prevent this interaction, magnesium and potassium levels should be monitored, and the patient's body stores of potassium and magnesium should be replenished even before the expected fall in serum potassium occurs.

References

  1. Miller R, Bates J "Amphotericin B toxicity." Ann Intern Med 71 (1969): 1089-95
  2. Cushard WG, Kohanim M, Lantis LR "Blastomycosis of bone." J Bone Joint Surg Am 51A (1969): 704-12
  3. "Product Information. Abelcet (amphotericin B lipid complex)." Liposome Company Inc, The
  4. "Product Information. Amphotec (amphotericin B cholesteryl sulfate)." Sequus Pharmaceuticals Inc (2022):
View all 4 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer